South Korea
· Delayed Price · Currency is KRW iNtRON Biotechnology Statistics
Total Valuation
iNtRON Biotechnology has a market cap or net worth of KRW 197.09 billion. The enterprise value is 141.00 billion.
| Market Cap | 197.09B |
| Enterprise Value | 141.00B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
iNtRON Biotechnology has 33.07 million shares outstanding. The number of shares has decreased by -0.86% in one year.
| Shares Outstanding | 33.07M |
| Shares Change (YoY) | -0.86% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 16.44% |
| Owned by Institutions (%) | 4.13% |
| Float | 27.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.79 |
| PB Ratio | 2.12 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -23.15 |
| EV / Sales | 15.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -24.11 |
Financial Position
The company has a current ratio of 43.03, with a Debt / Equity ratio of 0.00.
| Current Ratio | 43.03 |
| Quick Ratio | 41.91 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.07 |
| Interest Coverage | -4.14 |
Financial Efficiency
Return on equity (ROE) is -6.22% and return on invested capital (ROIC) is -1.71%.
| Return on Equity (ROE) | -6.22% |
| Return on Assets (ROA) | -1.69% |
| Return on Capital (ROIC) | -1.71% |
| Revenue Per Employee | 119.44M |
| Profits Per Employee | -80.15M |
| Employee Count | 76 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 3.60 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.20% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -16.20% |
| 50-Day Moving Average | 6,127.60 |
| 200-Day Moving Average | 6,823.50 |
| Relative Strength Index (RSI) | 48.53 |
| Average Volume (20 Days) | 70,934 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, iNtRON Biotechnology had revenue of KRW 9.08 billion and -6.09 billion in losses. Loss per share was -184.01.
| Revenue | 9.08B |
| Gross Profit | 5.70B |
| Operating Income | -3.15B |
| Pretax Income | -6.53B |
| Net Income | -6.09B |
| EBITDA | -1.10B |
| EBIT | -3.15B |
| Loss Per Share | -184.01 |
Balance Sheet
The company has 56.51 billion in cash and 419.17 million in debt, giving a net cash position of 56.09 billion or 1,696.15 per share.
| Cash & Cash Equivalents | 56.51B |
| Total Debt | 419.17M |
| Net Cash | 56.09B |
| Net Cash Per Share | 1,696.15 |
| Equity (Book Value) | 92.97B |
| Book Value Per Share | 2,811.41 |
| Working Capital | 58.23B |
Cash Flow
In the last 12 months, operating cash flow was 1.61 billion and capital expenditures -7.46 billion, giving a free cash flow of -5.85 billion.
| Operating Cash Flow | 1.61B |
| Capital Expenditures | -7.46B |
| Free Cash Flow | -5.85B |
| FCF Per Share | -176.81 |
Margins
Gross margin is 62.76%, with operating and profit margins of -34.71% and -67.10%.
| Gross Margin | 62.76% |
| Operating Margin | -34.71% |
| Pretax Margin | -71.90% |
| Profit Margin | -67.10% |
| EBITDA Margin | -12.16% |
| EBIT Margin | -34.71% |
| FCF Margin | -64.41% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 1.68%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 1.68% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | 0.86% |
| Shareholder Yield | 2.54% |
| Earnings Yield | -3.09% |
| FCF Yield | -2.97% |
Stock Splits
The last stock split was on January 10, 2019. It was a forward split with a ratio of 2.
| Last Split Date | Jan 10, 2019 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
iNtRON Biotechnology has an Altman Z-Score of 79.35.
| Altman Z-Score | 79.35 |
| Piotroski F-Score | n/a |